 Linzagolix

Linzagolix (; developmental code names KLH-2109, OBE-2109) is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis.As of December 2017, it is in phase III clinical trials for uterine fibroids and phase II clinical studies for endometriosis and adenomyosis.